Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Sep 21;108(6):2185–2192. doi: 10.1002/ccd.70905

Unprotected Left Main Disease: Clinical Outcomes Following Deferral, Coronary Artery Bypass Grafting, or Percutaneous Coronary Intervention

Marc Meller Bröchner 1,✉, Evald Høj Christiansen 2, Kristian Kragholm 1, Lisette Okkels Jensen 3, Gennady Atroshchenko 4, Ivy Susanne Modrau 5,6, Lars Riber 7, Oliver Buchhave Pedersen 1, Leif Thuesen 1, Christian Torp‐Pedersen 8,9, Ashkan Eftekhari 1
PMCID: PMC13756830  PMID: 42765913

ABSTRACT

Background

The prognostic benefit of revascularization for unprotected left main (LM) disease remains uncertain, as guideline endorsement of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) precludes comparison with deferral, which is unlikely to be assessed in a randomized trial.

Objectives

This study aimed to evaluate the prognostic impact of revascularization (PCI/CABG) versus deferred treatment of isolated, unprotected LM disease using real‐world data.

Methods

Patients with isolated, unprotected LM disease identified by invasive coronary angiography on the indication chronic coronary syndrome between January 2002 and January 2021, registered in the Western Denmark Heart Registry, were identified and split into four groups: Defer ≤ 50% stenosis, defer > 50% stenosis, PCI, or CABG. Acute coronary syndrome (ACS), revascularization, stroke, and all‐cause mortality risks within 5 years were assessed. Adjusted analyses were conducted.

Results

Of 4848 patients identified, 2819 patients underwent PCI, 467 CABG, 992 were in the defer ≤ 50% group, and 570 in defer > 50%. The 5‐year survival probability was 89.5% for PCI, 94.1% for CABG, 91.7% for defer ≤ 50%, and 84.0% for defer > 50% (p < 0.0005%). Cumulative incidence of ACS was 7.9% for PCI, 3.0% for CABG, 5.3% for defer ≤ 50%, and 8.2% for defer > 50% (p < 0.0005). For revascularization, numbers were 10.2%, 7.0%, 7.6%, and 15.4% (p < 0.0005) and stroke 3.6%, 2.1%, 2.5%, and 3.8% (p < 0.005). In adjusted analyses, the results were unchanged.

Conclusions

Using real‐world data, this study demonstrated that either PCI or CABG was associated with improved survival in patients with LM disease, when diameter stenosis exceeded 50%. PCI was associated with higher rates of non‐fatal ACS and repeat revascularization compared to CABG but similar rates as deferred treatment.

Clinical Perspectives

The prognostic benefit of revascularization for isolated and unprotected left main disease remains uncertain, as guideline endorsement of PCI or CABG precludes comparison with deferral. Deferred revascularization of unprotected LM disease with >50% diameter stenosis in patients with chronic coronary syndrome was associated with increased all‐cause mortality and non‐fatal acute coronary syndrome. Revascularization remains the treatment of choice in patients with significant unprotected LM disease for prognostic benefit.

1. Introduction

Both American and recent European guidelines recommend revascularization with coronary artery bypass grafting (CABG) of unprotected left main (LM) disease on prognostic indication, when the risk of surgical complications is low [1, 2]. Revascularization by percutaneous coronary intervention (PCI) is recommended when the SYNTAX score is low, and an equivalent degree of revascularization can be achieved compared to CABG [1, 2]. This recommendation is supported by data from randomized controlled trials of unprotected LM indicating equal all‐cause mortality risk of PCI versus CABG, and either equal risk of major adverse cardiovascular and cerebrovascular events (MACCE) or risk of MACCE favoring CABG [3, 4, 5]. A recent study from the Swedish SWEDEHEART registry demonstrated MACCE and mortality outcomes favoring CABG compared to PCI in patients with non‐ST‐elevation myocardial infarction and multivessel disease [6]. Importantly, only a fraction of eligible patients were enrolled in these studies [7]. No randomized controlled trial assessed revascularization with either CABG or PCI versus deferral, and recent trials comparing revascularization versus deferral excluded patients with LM disease [8, 9]. The Coronary Artery Surgery Study compared CABG versus initial medical therapy and showed reduced mortality, except when left ventricular systolic function was normal [10]. However, the study was conducted before the era of modern guideline‐directed medical therapy and contemporary PCI with second‐ and third‐generation drug‐eluting stents. As future randomized controlled trials on revascularization versus deferral of LM disease are unlikely to be conducted for ethical reasons, this study aimed to address this question using data from the Western Denmark Heart Registry (WDHR) in a large real‐world cohort. Therefore, we evaluated all‐cause mortality, acute coronary syndrome (ACS), repeat revascularization, and stroke in patients with stable LM disease undergoing CABG, PCI, or deferral of treatment. Central Illustration Illustration 1, 1.

Central Illustration 1.

Central Illustration 1

[Color figure can be viewed at wileyonlinelibrary.com]

Figure 1.

Figure 1

Flowchart of study population selection. [Color figure can be viewed at wileyonlinelibrary.com]

2. Methods

2.1. Study Population

The study population was derived from the WDHR. WDHR is a validated and extensive registry, including information on 95% to 99% of all invasive cardiac procedures performed in relation to ischemic heart disease in the western part of Denmark, covering approximately half of the country's population [11].

Patients from January 2002 to January 2021, with first‐time isolated and unprotected LM lesions, defined as isolated segment 5 on an elective invasive coronary angiography (ICA) on the indication of chronic coronary syndrome, were identified

Main exclusion criteria were ICAs without known information on degree of stenosis and emigration or immigration before the index ICA. Vital status, sex, and date of birth were collected using the Danish Civil Registration System [12]. This was linked to WDHR using the unique civil registration number assigned to all inhabitants in Denmark. In addition, this number was used to link data from the Danish National Patient Registry for outcome adjudication in addition to information used to assign each patient a Charlson comorbidity index [13]. Data from these registries were used to determine follow‐up. Additionally, baseline medication was assessed using information from the Danish National Prescription Registry was used to assess baseline medication use [14].

Hypertension, hyperlipidemia, and diabetes were defined as either registration in WDHR, by diagnosis code from the Danish National Patient Registry, or medication use, as done previously [15]. A complete list of Anatomical Therapeutic Chemical (ATC) drug classification and International Classification of Diseases (ICD) 10 codes used is provided in supplemental Table 1.

Table 1.

Baseline characteristics of the study population.

Variable Level CABG (n = 413) PCI (n = 2460) Defer, ≤50% stenosis (n = 862) Defer, >50% stenosis (n = 414) Total (n = 4149) p value
Sex Men 324 (78.5) 1782 (72.4) 515 (59.7) 285 (68.8) 2906 (70.0) < 0.0005
Age Mean (SD) 65.2 (9.5) 64.9 (11.1) 65.7 (10) 67.8 (10.5) 65.4 (10.7) < 0.0005
Smoking Yes 289 (74.9) 1488 (65.1) 518 (65.4) 247 (66.4) 2542 (66.3) < 0.005
Missing 27 (7) 175 (7) 70 (8) 42 (10) 314 (8)
Diabetes Yes 68 (17.4) 367 (15.5) 122 (14.9) 77 (19.5) 634 (16.0) 0.14
Missing 23 (6) 94 (4) 41 (5) 20 (5) 178 (4)
Hypertension Yes 242 (59.6) 1471 (60.7) 548 (64.5) 283 (70.8) 2544 (62.4) < 0.005
Missing 7 (2) 38 (2) 12 (1) 14 (3) 71 (2)
Hyperlipidemia Yes 304 (74.3) 1777 (72.9) 636 (74.5) 322 (79.5) 3039 (74.0) < 0.05
Missing 4 (1) 23 (1) 8 (1) 9 (2) 44 (1)
Family history of IHD Yes 186 (48.1) 1040 (45.2) 402 (49.3) 174 (46.4) 1802 (46.5) 0.22
Missing 26 (6) 161 (7) 46 (5) 39 (9) 272 (7)
BMI Mean (SD) 27.5 (4.1) 27.4 (4.4) 27.5 (4.8) 27.3 (4.2) 27.4 (4.4) 0.81
Missing 31 210 70 50 361
Charlson Comorbidity index Median [IQR] 0 [0, 1] 0 [0, 1] 0 [0, 1] 0 [0, 1] 0 [0, 1] < 0.0005
ASA Yes 255 (74.6) 1484 (74.2) 502 (69.1) 231 (67.2) 2472 (72.4) < 0.05
Missing 71 (17) 459 (19) 136 (16) 70 (17) 736 (18)
P2Y12‐inhibitor Yes 26 (7.6) 195 (9.7) 73 (10.1) 38 (11.0) 332 (9.7) 0.47
Missing 71 (17) 459 (19) 136 (16) 70 (17) 736 (18)
DOAC Yes 6 (1.8) 68 (3.4) 25 (3.4) 16 (4.7) 115 (3.4) 0.21
Missing 71 (17) 459 (19) 136 (16) 70 (17) 736 (18)
Diameter Stenosis (%) Median [IQR] 80 [70:90] 80 [70:90] 40 [30:50] 80 [65:100] 80 [50:90] < 0.0005

Abbreviations: ASA, acetylsalicylic acid; BMI, body mass index; DOAC, direct oral anticoagulants; IQR, inter quantile range; SD, standard deviation.

2.2. Exposure

2.2.1. Patients were Divided Into the Following Groups

  • 1.

    PCI

  • 2.

    CABG

  • 3.

    Deferred with diameter stenosis > 50%

  • 4.

    Deferred with diameter stenosis ≤ 50%

Patients were assigned to either CABG or PCI if a decision for the given intervention was made at the time of ICA or if they had an intervention within 90 days of their index ICA. A cutoff of 50% diameter stenosis was chosen to align with current guidelines [1, 2]. Degree of stenosis was defined according to the reported percentage in WDHR. No lower cutoff was chosen for deferred with diameter stenosis ≤ 50%.

2.3. Follow‐Up

Patients were followed after 90 days of event‐free survival until January 1, 2021, emigration, or occurrence of an outcome. The decision to include only patients with event‐free survival was made to avoid immortal time bias in the intervention groups, which could lead to an overestimation of the effectiveness of revascularization.

2.4. Study Endpoints

All‐cause mortality, ACS, revascularization, and stroke within 5 years were used as the primary outcome. All‐cause mortality was considered a competing risk in analyses where ACS, revascularization, and ischemic stroke were the outcomes. For list of ICD‐10 and procedure codes used to define outcomes is provided in supplemental Table 1.

2.5. Statistical Analysis

Median and 1st and 3rd quartile (IQR) or mean ± standard deviations (SD) were reported for continuous variables, while categorical variables were reported using counts and percentages. Probability estimates are reported as risk % (95% confidence interval). The former were compared using the Kruskal−Wallis test and the latter using the chi‐squared test. Cumulative incidence was estimated for outcomes with competing risk using the Aalen‐Johansen estimator, and for mortality the 1‐Kaplan−Meier estimator at 5 years was presented as curves.

Information on outcomes among patients excluded within the first 90 days was reported.

Using multivariate Cox regression models, the association between the defer, PCI, and CABG groups was compared. These models were adjusted for age at index ICA, sex, diabetes, hypertension, smoking status, and hyperlipidemia. Subsequently, average adjusted absolute 5‐year risk of all outcomes, in percentage, according to defer, PCI, and CABG groups was derived using g‐formula methods and presented using bar plots [16].

Trends for stenosis degree and Charlson comorbidity index according to exposure, through the study period, were assessed using line charts.

Additionally, analyses were stratified by diabetes, sex, ICA before/after 2012, estimated glomerular filtration rate (eGFR) above or below 90, smoking status and BMI above or below 30.

Models stratified by smoking status and diabetes were not adjusted for variables on which models were stratified.

Statistical significance was defined as a two‐tailed p‐value < 0.05 and analyses were conducted using R version 4.4.1 (R Foundation, Austria), and g‐formula methods were done using the package “riskRegression” [17].

2.6. Ethical Approval

The Capital Region of Denmark approved the present study. Informed consent or ethical approvement for registry‐based studies is not required in Denmark.

3. Results

3.1. Study Population

A total of 4149 patients were identified after applying exclusion criteria. The consort diagram of the study is shown in Figure Illustration 1, 1. The study population consisted of 413 patients who underwent CABG, 2460 who underwent PCI, 862 were in the defer group with ≤50% stenosis, and 414 in the >50% group (Table 1). Median diameter stenoses were: CABG: 80% (IQR 70%; 90%), PCI: 80% (IQR 70%; 90%), Defer ≤ 50%: 40% (IQR 30%; 50%) Defer > 50%: 80% (IQR 50%; 90%) (p < 0.0005) (Table 1).

Number of outcomes between ICA and 90 days after is reported in Table S2. In brief differences for all‐cause mortality within 90 days were insignificant (p = 0.185). The number of strokes was too low to report due to microdata. Although strokes were numerically more common in the CABG group, the differences were insignificant (p = 0.27). More patients undergoing CABG were excluded due to ACS (11.1%) and repeat revascularization (3.9%) compared with PCI (8.0% and 3.1%) (p < 0.0005).

Patients in both defer groups were more likely to be female compared with both the CABG and PCI groups. In all groups, the age was similar, though statistically significantly different (Table 1). The defer ≤ 50% group comprised of more patients with hypertension, hyperlipidemia and who were less likely to take acetylsalicylic acid at baseline, compared with all other groups (Table 1). P2Y12‐inhibitor and direct oral anticoagulant use was similar across groups (Table 1).

Of patients assigned for CABG during initial ICA, 36 (1.3%) underwent PCI, and among patients assigned for PCI 10 (2.1%) underwent CABG (p < 0.0005). Among patients who underwent CABG, median EUROSCORE2 was 0.9 (IQR 0.6:1.3) (Table 1). Among patients assigned for CABG following initial ICA, but who instead cross‐over to PCI, the corresponding score was 0.9 (IQR 0.6:1.1) (p = 0.48).

3.2. Risks

The 5‐year cumulative all‐cause mortality was 10.5% (9.3%−11.7%) for patients receiving PCI, 5.9% (3.6%−8.3%) for CABG, 8.3% (6.4%−10.2%) for defer ≤ 50% and 16.0% (12.3%−19.8%) for defer > 50% (p < 0.0005%) (Figure 2). Cumulative incidence of ACS at 5‐years was 7.9% (6.8%−9.0%) for patients receiving PCI, 3.0% (1.3%−4.8%) for CABG, 5.3% (3.8%−6.9%) for defer ≤ 50% and 8.2% (5.4%−10.9%) for defer > 50% (p < 0.0005%) (Figure 2). For revascularization, the numbers were 10.2% (8.9%−11.4%), 7.0% (4.5%−9.5%), 7.6% (5.8%−9.4%) and 15.4% (11.9%−19.0%) (p < 0.0005) and for stroke 3.6% (2.8%−4.3%), 2.1% (0.7%−3.6%), 2.5% (1.4%−3.6%) and 3.8% (1.9%−5.7%), (p < 0.005).

Figure 2.

Figure 2

5‐year cumulative incidence and survival curves for outcomes in patients with 90 days event‐free survival. Survival is from all‐cause mortality. [Color figure can be viewed at wileyonlinelibrary.com]

3.3. Adjusted Risks for Mortality, ACS and Stroke

In adjusted analyses, the absolute risk for all‐cause mortality at 5 years was for PCI: 12.7% (12.0%−13.4%), CABG: 11.6% (11.0%−12.2%), defer ≤ 50%: 13.2% (12.2%−14.3%) and defer > 50%: 15.4% (14.2%−16.5%) (Figure 3).

Figure 3.

Figure 3

Adjusted absolute risks of outcomes at 5 years. NS, not significant, *p < 0.05, **p < 0.005, ***p < 0.0005. [Color figure can be viewed at wileyonlinelibrary.com]

The absolute risk of ACS was 10.7% (9.9%−11.5%) for patients receiving PCI, 5.2% (4.8%−5.8%) for CABG, 8.3% (7.2%−9.5%) for defer ≤ 50%, and 12.2% (10.7%−13.6%) for defer > 50%. For revascularization, the numbers were PCI: 18.6% (17.6%−19.6%), CABG: 9.4% (8.7%−10.1%), defer ≤ 50%: 14.9% (13.3%−16.4%) and defer > 50%: 19.5% (17.5%−21.4%). For stroke, numbers were PCI: 4.1% (3.6%−4.6%), CABG: 4.4% (3.9%−4.8%), defer ≤ 50%: 4.1% (3.4%−4.9%) and defer > 50%: 4.8% (3.9%−5.7%).

3.4. Sensitivity Analyses

Results for sensitivity analyses are found in supplemental material (Figures Illustration 1, 1). Among men, results remained unchanged from the main results (Figure Illustration 1, 1). In subgroup analyses for women, a similar risk of ACS and repeat revascularization was found among women with a diameter stenosis ≤ 50% and those who underwent CABG (Figure S2). When stratified on kidney function, patients with an eGFR < 60, had a higher risk of all‐cause mortality (Figure S3). In patients with an eGFR ≥ 60, both defer groups and the PCI group had a similar all‐cause mortality risk (Figure S4).

In analyses stratified on diabetes, results remained unchanged from the primary results, though risk for all outcomes were higher among patients suffering from diabetes (Figures S5, S6). When assessing risks before and after 2012, a similar all‐cause mortality risk was found between the two defer groups and PCI after 2012 (Figures S7, S8). Assessing patients according to smoking status, a similar risk of revascularization among groups was found for patients who did not smoke (Figures S9, S10). When stratifying models based on BMI above and below 30, results were largely unchanged (Figures S11, S12).

3.5. Loss to Follow‐Up

For analyses on death, 30 patients were lost to follow‐up due to emigration, for stroke and ACS, the number was 29 and for revascularization, the number was 27.

3.6. Trends

Degree of stenosis on initial ICA remained stable through the study period across all four groups (Figure S13). Charlson comorbidity index fell across all groups except CABG (Figure S14).

4. Discussion

Using real‐world data, the present study evaluated the risk of all‐cause mortality, stroke, ACS, and repeat revascularization in patients with unprotected LM disease undergoing CABG, PCI, or deferral of revascularization. The primary finding was that revascularization of unprotected LM was associated with better survival and lower risk of ACS and was consistent across adjusted and unadjusted analyses. CABG was associated with more favorable outcomes compared to PCI and deferral. Furthermore, patients undergoing PCI had better survival and a similar risk of ACS and repeat revascularization compared to deferred patients with a diameter stenosis > 50%. The risk of all‐cause mortality was similar in patients undergoing PCI and those with a diameter stenosis ≤ 50% for whom treatment was deferred, despite the PCI group having a mean diameter stenosis of 75.2%.

The study further found that the degree of stenosis in patients selected for PCI and CABG remained stable through the study period. The inclusion of patients with deferred treatment in this study expands the current literature and addresses a knowledge gap unlikely to be filled by randomized controlled trials.

CABG has been found to be associated with an increased risk of post‐operative stroke and myocardial infarction [18]. In the present study, we found a lower risk of all outcomes except for stroke, which was similar between all groups. This finding was confirmed in multiple sensitivity analyses. However, the study assessed 90‐day event‐free survival only, to account for immortal time bias. A similar number of strokes was found when assessment of outcomes within 90 days was done, however, this difference was statistically insignificant. This confirms previous findings, but adds that patients with event‐free survival have similar risks of stroke across groups [19].

PCI of LM lesions > 50% was associated with lower all‐cause mortality and was comparable to deferred patients with ≤50% diameter stenosis. Usually, it is difficult to demonstrate survival benefit of revascularization in patients with chronic coronary artery disease. However, many of these studies exclude patients with LM disease [8, 9]. The current results indicate that unprotected LM disease should still be considered a malignant condition mandating revascularization with either PCI or CABG as appropriate. The results further indicate that the current practice when selecting patients for PCI or CABG is efficient. The similar risk of ACS and revascularization combined with a lower risk of all‐cause mortality in patients undergoing PCI compared with defer patients with a diameter stenosis > 50% indicates that revascularization should be the treatment of choice in patients with significant unprotected LM stenosis.

The recent randomized controlled trials on management of LM disease evaluated revascularization with either PCI or CABG only. In the Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of LM Revascularization (EXCEL) trial, there was no difference in the composite endpoint (death, myocardial infarction or stroke) between the CABG and PCI arm [18]. However, there was an absolute difference of 3.1% in all‐cause death in favor of CABG [18]. In the current study, CABG was also associated with lower mortality although the difference narrowed in adjusted analyses. In the Nordic‐Baltic LM Revascularization Study (NOBLE), CABG and PCI had equal survival at 5 years, with PCI being non‐inferior in terms of myocardial infarction and repeat revascularization [4]. Neither the EXCEL nor the NOBLE trials evaluated revascularization versus deferral of treatment, as deferred treatment of significant LM disease has been considered unethical. However, the results of the International Study of Comparative Effectiveness with Medical and Invasive Approaches (ISCHEMIA) and Objective Randomized Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trials might suggest evaluation of a conservative strategy in LM patients with chronic coronary syndrome [8, 9]. However, this strategy cannot be extrapolated to LM disease, as neither trial included patients with LM disease or in any way deemed suitable for CABG based on the extent of coronary artery disease. The results of the current study highlight that deferral of significant LM disease is associated with poor outcome despite stable chronic coronary syndrome.

The present study also shows that women are more likely to be represented in the defer group. This might be a representation of the known gender gap, which for CABG is being addressed by the ongoing ROMA: Women trial [20]. In the present study, favorable outcomes in women were found across groups in sensitivity analyses on gender.

5. Limitations

As the present study assesses data from the real‐world, selection bias might be present, as patients who are fit for surgery might have a better prognosis due to this. Furthermore, the fact that patients undergoing PCI have better outcomes compared to the defer group might be due to selection bias and residual confounding.

The observational nature of the present study hinders causal and only allows for associative interpretation of the results. However, the results of the study are in line with the current evidence, and use well‐validated, real‐life data to assess a knowledge gap, in a patient population where a clinical study is unlikely.

6. Conclusion

Using real‐world data, the present study evaluated patients undergoing revascularization or deferred treatment for unprotected LM disease and demonstrated that revascularization with either PCI or CABG was associated with improved survival when LM diameter stenosis exceeded 50%. PCI was associated with higher rates of non‐fatal ACS and repeat revascularization compared to CABG but similar rates as deferred treatment, when LM diameter stenosis exceeded 50%.

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

Supporting File 1

CCD-108-2185-s009.pdf (5.3KB, pdf)

Supporting File 2

CCD-108-2185-s005.pdf (5.3KB, pdf)

Supporting File 3

CCD-108-2185-s001.pdf (5.2KB, pdf)

Supporting File 4

CCD-108-2185-s006.pdf (5.3KB, pdf)

Supporting File 5

CCD-108-2185-s015.pdf (5.3KB, pdf)

Supporting File 6

CCD-108-2185-s013.pdf (5.3KB, pdf)

Supporting File 7

CCD-108-2185-s012.pdf (5.3KB, pdf)

Supporting File 8

CCD-108-2185-s002.pdf (5.3KB, pdf)

Supporting File 9

CCD-108-2185-s004.pdf (5.3KB, pdf)

Supporting File 10

CCD-108-2185-s011.pdf (5.3KB, pdf)

Supporting File 11

CCD-108-2185-s014.pdf (5.3KB, pdf)

Supporting File 12

CCD-108-2185-s010.pdf (5.3KB, pdf)

Supporting File 13

CCD-108-2185-s007.pdf (9.5KB, pdf)

Supporting File 14

CCD-108-2185-s003.pdf (9.9KB, pdf)

Supporting File 15

CCD-108-2185-s008.docx (1.7MB, docx)

Data Availability Statement

The data that support the findings of this study are available from relevant Danish authorities. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the author(s) with the permission of relevant Danish authorities.

References

  • 1. Virani S. S., Newby L. K., Arnold S. V., et al., 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, 2023. [DOI] [PubMed]
  • 2. Vrints C., Andreotti F., Koskinas K. C., et al., “2024 ESC Guidelines for the Management of Chronic Coronary Syndromes,” European Heart Journal 45 (2024): 3415–3537, 10.1093/eurheartj/ehae177. [DOI] [PubMed] [Google Scholar]
  • 3. Gaudino M., Farkouh M. E., and Stone G. W., “Left Main Revascularization: An Evidence‐Based Reconciliation,” European Heart Journal 43 (2022): 2421–2424, 10.1093/eurheartj/ehac216. [DOI] [PubMed] [Google Scholar]
  • 4. Holm N. R., Mäkikallio T., Lindsay M. M., et al., “Percutaneous Coronary Angioplasty Versus Coronary Artery Bypass Grafting in the Treatment of Unprotected Left Main Stenosis: Updated 5‐year Outcomes From the Randomised, Non‐Inferiority NOBLE Trial,” Lancet 395 (2020): 191–199, 10.1016/S0140-6736(19)32972-1. [DOI] [PubMed] [Google Scholar]
  • 5. Morice M.‐C., Serruys P. W., Kappetein A. P., et al., “Outcomes in Patients with De Novo Left Main Disease Treated with Either Percutaneous Coronary Intervention Using Paclitaxel‐Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) Trial,” Circulation 121 (2010): 2645–2653, 10.1161/CIRCULATIONAHA.109.899211. [DOI] [PubMed] [Google Scholar]
  • 6. Persson J., Yan J., Angerås O., et al., “PCI or CABG for Left Main Coronary Artery Disease: The SWEDEHEART Registry,” European Heart Journal 44 (2023): 2833–2842, 10.1093/eurheartj/ehad369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Serruys P. W., Morice M.‐C., Kappetein A. P., et al., “Percutaneous Coronary Intervention Versus Coronary‐Artery Bypass Grafting for Severe Coronary Artery Disease,” New England Journal of Medicine 360 (2009): 961–972, 10.1056/NEJMoa0804626. [DOI] [PubMed] [Google Scholar]
  • 8. Jafary F. H. and Jafary A. H., “Ischemia Trial: Does the Cardiology Community Need to Pivot or Continue Current Practices?,” Current Cardiology Reports 24 (2022): 1059–1068, 10.1007/s11886-022-01725-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Al‐Lamee R., Thompson D., Dehbi H.‐M., et al., “Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double‐Blind, Randomised Controlled Trial,” Lancet 391 (2018): 31–40, 10.1016/S0140-6736(17)32714-9. [DOI] [PubMed] [Google Scholar]
  • 10. Caracciolo E. A., Davis K. B., Sopko G., et al., “Comparison of Surgical and Medical Group Survival in Patients with Left Main Equivalent Coronary Artery Disease: Long‐Term CASS Experience,” Circulation 91 (1995): 2335–2344, 10.1161/01.CIR.91.9.2335. [DOI] [PubMed] [Google Scholar]
  • 11. Schmidt M., Maeng M., Madsen M., Sørensen H. T., Jensen L. O., and Jakobsen C. J., “The Western Denmark Heart Registry,” Journal of the American College of Cardiology 71 (2018): 1259–1272, 10.1016/j.jacc.2017.10.110. [DOI] [PubMed] [Google Scholar]
  • 12. Pedersen C. B., “The Danish Civil Registration System,” Scandinavian Journal of Public Health 39 (2011): 22–25, 10.1177/1403494810387965. [DOI] [PubMed] [Google Scholar]
  • 13. Schmidt M., Schmidt S. A. J., Sandegaard J. L., Ehrenstein V., Pedersen L., and Sørensen H. T., “The Danish National Patient Registry: A Review of Content, Data Quality, and Research Potential,” Clinical Epidemiology 7 (2015): 449–490, 10.2147/CLEP.S91125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Wallach Kildemoes H., Toft Sørensen H., and Hallas J., “The Danish National Prescription Registry,” Scandinavian Journal of Public Health 39 (2011): 38–41, 10.1177/1403494810394717. [DOI] [PubMed] [Google Scholar]
  • 15. Olesen J. B., Lip G. Y. H., Hansen M. L., et al., “Validation of Risk Stratification Schemes for Predicting Stroke and Thromboembolism in Patients with Atrial Fibrillation: Nationwide Cohort Study,” BMJ 342 (2011): d124, 10.1136/bmj.d124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Ozenne B. M. H., Scheike T. H., Stærk L., and Gerds T. A., “On the Estimation of Average Treatment Effects With Right‐Censored Time to Event Outcome and Competing Risks,” Biometrical Journal 62 (2020): 751–763, 10.1002/bimj.201800298. [DOI] [PubMed] [Google Scholar]
  • 17. R Core Team . 2023. R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing, Vienna, Austria, https://www.r-project.org/.
  • 18. Stone G. W., Kappetein A. P., Sabik J. F., et al., “Five‐Year Outcomes After PCI or CABG for Left Main Coronary Disease,” New England Journal of Medicine 381 (2019): 1820–1830, 10.1056/NEJMoa1909406. [DOI] [PubMed] [Google Scholar]
  • 19. Palmerini T., Biondi‐Zoccai G., Reggiani L. B., et al., “Risk of Stroke with Coronary Artery Bypass Graft Surgery Compared with Percutaneous Coronary Intervention,” Journal of the American College of Cardiology 60 (2012): 798–805, 10.1016/j.jacc.2011.10.912. [DOI] [PubMed] [Google Scholar]
  • 20. Gaudino M., Fremes S. E., Mehran R., and Bairey Merz C. N., “ROMA: Women: Innovative Approaches for the First Cardiac Surgery Trial in Women,” Circulation 148 (2023): 1289–1291, 10.1161/CIRCULATIONAHA.123.064033. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting File 1

CCD-108-2185-s009.pdf (5.3KB, pdf)

Supporting File 2

CCD-108-2185-s005.pdf (5.3KB, pdf)

Supporting File 3

CCD-108-2185-s001.pdf (5.2KB, pdf)

Supporting File 4

CCD-108-2185-s006.pdf (5.3KB, pdf)

Supporting File 5

CCD-108-2185-s015.pdf (5.3KB, pdf)

Supporting File 6

CCD-108-2185-s013.pdf (5.3KB, pdf)

Supporting File 7

CCD-108-2185-s012.pdf (5.3KB, pdf)

Supporting File 8

CCD-108-2185-s002.pdf (5.3KB, pdf)

Supporting File 9

CCD-108-2185-s004.pdf (5.3KB, pdf)

Supporting File 10

CCD-108-2185-s011.pdf (5.3KB, pdf)

Supporting File 11

CCD-108-2185-s014.pdf (5.3KB, pdf)

Supporting File 12

CCD-108-2185-s010.pdf (5.3KB, pdf)

Supporting File 13

CCD-108-2185-s007.pdf (9.5KB, pdf)

Supporting File 14

CCD-108-2185-s003.pdf (9.9KB, pdf)

Supporting File 15

CCD-108-2185-s008.docx (1.7MB, docx)

Data Availability Statement

The data that support the findings of this study are available from relevant Danish authorities. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the author(s) with the permission of relevant Danish authorities.


Articles from Catheterization and Cardiovascular Interventions are provided here courtesy of Wiley

RESOURCES